PMC:7105881 / 57061-57219 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1724","span":{"begin":62,"end":70},"obj":"Species"},{"id":"1725","span":{"begin":75,"end":83},"obj":"Species"}],"attributes":[{"id":"A1724","pred":"tao:has_database_id","subj":"1724","obj":"Tax:694009"},{"id":"A1725","pred":"tao:has_database_id","subj":"1725","obj":"Tax:1335626"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"al., 2017).\n\nPotential Challenges and Future Perspectives for Sars-CoV and Mers-CoV Subunit Vaccines\nCompared with other vaccine types such as inactivated vir"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T274","span":{"begin":62,"end":70},"obj":"Disease"}],"attributes":[{"id":"A274","pred":"mondo_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"al., 2017).\n\nPotential Challenges and Future Perspectives for Sars-CoV and Mers-CoV Subunit Vaccines\nCompared with other vaccine types such as inactivated vir"}

{"project":"LitCovid-sentences","denotations":[{"id":"T304","span":{"begin":13,"end":100},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"al., 2017).\n\nPotential Challenges and Future Perspectives for Sars-CoV and Mers-CoV Subunit Vaccines\nCompared with other vaccine types such as inactivated vir"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T948","span":{"begin":62,"end":66},"obj":"PR:000014459;SP_10"},{"id":"T949","span":{"begin":66,"end":70},"obj":"SP_10"},{"id":"T950","span":{"begin":75,"end":83},"obj":"SP_9"},{"id":"T90797","span":{"begin":62,"end":66},"obj":"PR:000014459;SP_10"},{"id":"T13411","span":{"begin":66,"end":70},"obj":"SP_10"},{"id":"T49408","span":{"begin":75,"end":83},"obj":"SP_9"}],"text":"al., 2017).\n\nPotential Challenges and Future Perspectives for Sars-CoV and Mers-CoV Subunit Vaccines\nCompared with other vaccine types such as inactivated vir"}